Annie Purvis

801 total citations
12 papers, 532 citations indexed

About

Annie Purvis is a scholar working on Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health and Ophthalmology. According to data from OpenAlex, Annie Purvis has authored 12 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 4 papers in Public Health, Environmental and Occupational Health and 3 papers in Ophthalmology. Recurrent topics in Annie Purvis's work include Multiple Sclerosis Research Studies (4 papers), Pregnancy and Medication Impact (4 papers) and Retinal and Optic Conditions (3 papers). Annie Purvis is often cited by papers focused on Multiple Sclerosis Research Studies (4 papers), Pregnancy and Medication Impact (4 papers) and Retinal and Optic Conditions (3 papers). Annie Purvis collaborates with scholars based in United States, France and Canada. Annie Purvis's co-authors include P W Belfield, N J Cooke, A G Arnold, F G Simpson, M F Muers, David Margolin, Alasdair Coles, Pedro Oyuela, Abraham Scaria and Ronald Buggage and has published in prestigious journals such as The Lancet, Blood and Neurology.

In The Last Decade

Annie Purvis

12 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Annie Purvis United States 8 163 138 136 117 80 12 532
Kenichi Hoshi Japan 13 98 0.6× 35 0.3× 52 0.4× 77 0.7× 86 1.1× 31 510
Özgür İlhan Türkiye 13 51 0.3× 20 0.1× 51 0.4× 249 2.1× 33 0.4× 42 488
Ofira Zloto Israel 14 86 0.5× 82 0.6× 63 0.5× 388 3.3× 25 0.3× 96 710
Hatice Tuba Atalay Türkiye 14 106 0.7× 49 0.4× 58 0.4× 425 3.6× 12 0.1× 50 552
Akiko Suda Japan 10 36 0.2× 35 0.3× 147 1.1× 191 1.6× 63 0.8× 20 459
Oded Sagiv United States 16 86 0.5× 85 0.6× 26 0.2× 325 2.8× 79 1.0× 49 695
Agnès Liprandi France 12 97 0.6× 22 0.2× 94 0.7× 16 0.1× 53 0.7× 33 442
Jane S. Kim United States 11 95 0.6× 88 0.6× 23 0.2× 139 1.2× 26 0.3× 45 404
Kenneth P. Cheng United States 13 42 0.3× 53 0.4× 24 0.2× 329 2.8× 33 0.4× 18 612

Countries citing papers authored by Annie Purvis

Since Specialization
Citations

This map shows the geographic impact of Annie Purvis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Purvis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Purvis more than expected).

Fields of papers citing papers by Annie Purvis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Purvis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Purvis. The network helps show where Annie Purvis may publish in the future.

Co-authorship network of co-authors of Annie Purvis

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Purvis. A scholar is included among the top collaborators of Annie Purvis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Purvis. Annie Purvis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Henson, Lily Jung, et al.. (2020). Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. Reproductive Toxicology. 95. 45–50. 10 indexed citations
2.
Miller, Aaron, Tomas Olsson, Jerry S. Wolinsky, et al.. (2020). Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. Multiple Sclerosis and Related Disorders. 46. 102438–102438. 16 indexed citations
3.
Miller, Aaron, Patrick Vermersch, Ludwig Kappos, et al.. (2019). Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★. Multiple Sclerosis and Related Disorders. 33. 131–138. 16 indexed citations
4.
Vukusic, Sandra, Patricia K. Coyle, Stéphanie Jurgensen, et al.. (2019). Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Multiple Sclerosis Journal. 26(7). 829–836. 41 indexed citations
5.
Campochiaro, Peter A., Jeffrey S. Heier, Pravin U. Dugel, et al.. (2017). 3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 58(8). 2321–2321. 2 indexed citations
6.
Miller, Aaron, Mark Freedman, Jiwon Oh, et al.. (2017). Outcomes of the TOPIC Extension Study of Teriflunomide in Patients With Early Multiple Sclerosis: Up to 7 Years of Clinical Results (P2.103). Neurology. 88(16_supplement). 2 indexed citations
7.
Heier, Jeffrey S., Saleema Kherani, Shilpa J. Desai, et al.. (2017). Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. The Lancet. 390(10089). 50–61. 181 indexed citations
8.
Kremenchutzky, Marcelo, Mark Freedman, Amit Bar‐Or, et al.. (2016). Final Outcomes of the Teriflunomide Phase 2 Extension Study: 13 Years of Efficacy and Safety Results (P3.027). Neurology. 86(16_supplement). 1 indexed citations
9.
10.
Meyer, David, Alasdair Coles, Pedro Oyuela, Annie Purvis, & David Margolin. (2012). Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing–remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 2(1). 60–63. 29 indexed citations
11.
Cuker, Adam, Alasdair Coles, H. R. Sullivan, et al.. (2011). A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 118(24). 6299–6305. 79 indexed citations
12.
Simpson, F G, A G Arnold, Annie Purvis, et al.. (1986). Postal survey of bronchoscopic practice by physicians in the United Kingdom.. Thorax. 41(4). 311–317. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenichi Hoshi Breakdown of academic impact, for papers by Özgür İlhan Breakdown of academic impact, for papers by Ofira Zloto Breakdown of academic impact, for papers by Hatice Tuba Atalay Breakdown of academic impact, for papers by Akiko Suda Breakdown of academic impact, for papers by Oded Sagiv Breakdown of academic impact, for papers by Agnès Liprandi Breakdown of academic impact, for papers by Jane S. Kim Breakdown of academic impact, for papers by Kenneth P. Cheng
Rankless by CCL
2026